By: J. Collins PhD
At ESMO 2024, there were several sessions dedicated to haematological malignancies as well as CAR-T-cells and bispecifics in various haematological disorders. Here, the highlights of these talks are outlined.
(BELG J HEMATOL 2024;15(7):298–301)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
